Sanofi SA Unsponsored Canadian Depositary Receipt Hedged Reg S logo

Sanofi SA Unsponsored Canadian Depositary Receipt Hedged Reg S (SNW0)

Market Open
7 Aug, 20:00
XDUS XDUS
11. 80
+0.2
+1.7241%
- Market Cap
- P/E Ratio
8.15% Div Yield
0 Volume
- Eps
11.6
Previous Close
Add Transaction
Day Range
11.2 11.8
Year Range
10.8 13.27
Want to track SNW0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SNW0 trading today higher at €11.8, an increase of 1.7241% from yesterday's close, completing a monthly increase of 5.3571% or €0.6. Over the past 12 months, SNW0 stock lost -4.8387%.
SNW0 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on TSX (CAD).

SNW0 Chart

Sanofi SA Unsponsored Canadian Depositary Receipt Hedged Reg S (SNW0) FAQ

What is the stock price today?

The current price is €11.80.

On which exchange is it traded?

Sanofi SA Unsponsored Canadian Depositary Receipt Hedged Reg S is listed on XDUS.

What is its stock symbol?

The ticker symbol is SNW0.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 8.15%.

What is its market cap?

As of today, no market cap data is available.

Has Sanofi SA Unsponsored Canadian Depositary Receipt Hedged Reg S ever had a stock split?

No, there has never been a stock split.

Sanofi SA Unsponsored Canadian Depositary Receipt Hedged Reg S Profile

Pharmaceuticals Industry
Healthcare Sector
Belén Garijo López CEO
XDUS Exchange
- ISIN
FR Country
76,493 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Sanofi is a global leader in healthcare, deeply engaged in the journey of pushing the boundaries of medicine to improve health outcomes across the world. Founded in 1973 and headquartered in Paris, France, the company has evolved its name from Sanofi-Aventis to Sanofi in May 2011, marking a milestone in its expansive history. With a robust presence in the United States, Europe, and various international markets, Sanofi undertakes the research, development, manufacture, and marketing of therapeutic solutions through a comprehensive portfolio segmented into Pharmaceuticals, Vaccines, and Consumer Healthcare. The company's dedication to innovation is underscored by its collaborations, including a notable one with GlaxoSmithKline for a Covid-19 vaccine and a research venture with Stanford University School of Medicine focused on immunology and inflammation. Furthermore, Sanofi's partnership with Prellis Biologics, Inc., showcases its commitment to exploring new horizons in healthcare solutions.

Products and Services

  • Specialty Care Products: Sanofi delivers cutting-edge treatments in various therapeutic areas. This includes human monoclonal antibodies, treatments for multiple sclerosis, neurology, inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders. These products underline Sanofi's commitment to addressing complex health conditions with innovative solutions.
  • Diabetes and Cardiovascular Products: The company offers a range of medicines for diabetes care, showcasing its role in battling this global epidemic. Additionally, it provides products for cardiovascular health, emphasizing the importance of managing heart-related conditions.
  • Vaccines: With an emphasis on public health, Sanofi supplies vaccines for poliomyelitis, pertussis, and Hib for children; influenza, adult boosters, meningitis, and vaccines for travel and endemic diseases for adults, highlighting its role in preventing infectious diseases across all age groups.
  • Consumer Healthcare: Beyond prescription medicines, Sanofi extends its healthcare solutions to over-the-counter products. This includes allergy relief, cough and cold therapies, pain management, liver care, products promoting physical and mental wellness, probiotics, digestive health, and nutritional products. The range also features daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema, catering to a wide array of consumer health needs.
  • Pharmaceutical Products and Vaccines in Development: Sanofi is actively involved in the development of new pharmaceuticals and vaccines, pointing to a future of continued innovation and enhanced healthcare solutions. This commitment to research and development ensures Sanofi remains at the forefront of addressing emerging health challenges.

Contact Information

Address: 46, Avenue de la Grande-Armée
Phone: 33 1 53 77 40 00